A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma

This phase I/II dose-escalation study investigated the all-oral ixazomib-melphalan-prednisone regimen, followed by single-agent ixazomib maintenance, in elderly, transplant-ineligible patients with newly diagnosed multiple myeloma. Primary phase I objectives were to determine the safety and recommen...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Haematologica
Asıl Yazarlar: San-Miguel, Jesús F., Echeveste Gutierrez, Maria-Asunción, Špicka, Ivan, Mateos, María-Victoria, Song, Kevin, Craig, Michael D., Bladé, Joan, Hájek, Roman, Chen, Christine, Di Bacco, Alessandra, Estevam, Jose, Gupta, Neeraj, Byrne, Catriona, Lu, Vickie, van de Velde, Helgi, Lonial, Sagar
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Ferrata Storti Foundation 2018
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6119151/
https://ncbi.nlm.nih.gov/pubmed/29954932
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2017.185991
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller